PF-05089771

PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.[1][2] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.[3]

See also

References

  1. McMahon, Stephen; Koltzenburg, Martin; Tracey, Irene; Turk, Dennis C. (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0.
  2. Martz, Lauren (2014). "Nav-i-gating antibodies for pain". Science-Business eXchange 7 (23). doi:10.1038/scibx.2014.662. ISSN 1945-3477.
  3. Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.


This article is issued from Wikipedia - version of the Wednesday, March 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.